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Several cases have been reported of patients with immune-
mediated subepidermal blistering disorders whose autoanti-
bodies react to antigens present on both the dermal and epi-
dermal side of 1 M NaCI-split skin. In this report, we 
identify, localize, and characterize the basement membrane 
zone antigen corresponding to the dermal staining in a pa-
tient whose serum stains both the dermal and epidermal side 
of 1 M NaCI-split skin. This patient's serum contains auto-
antibodies directed against a 10S-kilodalton{kDa) dermal an-
tigen and the 230-kDa epidermal (bullous permphigoid) an-
tigen. This novel 10S-kDa protein was previously identified 
as the sole antigen in another patient with a unique bullous 
disease whose autoantibodies were directed against only the 
dermal side of 1 M NaCl-split skin. This 10S-kDa antigen 
was identical by one- and two-dimensional immunoblot 
analysis in these two patients. By immunoblot analysis, auto-
antibodies from our patient labeled a 1 05-kDa protein within 
various extracts of human skin basement membrane. Im-
munoblot analyses using epitope-selected autoantibodies di-
I mmune-mediated subepidermal bullous dermatoses are characterized by the patients' clinical presentation and the specific basement membrane antigens targeted by their auto-antibodies. Currently identified basement membrane au-to antigens associated with immune-mediated subepidermal 
bullous dermatoses include the bullous pemphigoid antigens (230-
kilodalton[kDa] and 180-kDa antigens) [1 - 3], epidermolysis bul-
losa acquisita antigen (type VII collagen) [4 - 6], nicein (identified 
by circulating autoantibodies in some atypical cases of cicatricial 
pemphigoid) [7]. the 97-kDa antigen targeted by autoantibodies in 
some cases of linear immunoglobulin (Ig)A bullous dermatosis [8], 
and a novel 105-kDa basement membrane autoantigen recently 
identified as the sole antigen in a patient with a unique bullous 
disease [9]. 
Several cases of patients with immune-mediated subepidermal 
blistering disorders whose autoantibodies bind to both dermal and 
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rected against the 10S-kDa protein demonstrated that this 
antigen is independent and distinct from other known base-
ment membrane antigens. The lOS-kDa antigen is an extra-
cellular matrix component of the basement membrane, 
which is synthesized and secreted by both keratinocytes and 
fibroblasts. Identical electrophoretic migration of cellular 
and secreted forms of the protein suggested there is no major 
post-translational modification of the protein. Immunomap-
ping of normal human skin fractured through the dermal-
epidermal junction by incubation in 1 M NaCI or by suction 
blistering demonstrated that the location of the lOS-kDa 
antigen within the basement membrane zone is between the 
bullous pemphigoid antigens and two other lamina lucida 
components, laminin and nicein. These data demonstrate 
clearly that a subepidermal autoimmune bullous disease may 
have autoantibodies directed against two distinct compo-
nents of the dermal-epidermal junction. Key words: bul/otls 
pemphigoid/dermal-epidermal junction/salt-split skin. ] Invest 
DermatoI103:78-83,1994 
epidermal sides of the dermal-epidermal junction (DE]) have been 
reported by indirect immunofluorescence (II F) on 1 M NaCI-split 
skin (SSS) [10 - 13]. In all cases, the epidermal staining of the DE] 
corresponded to the bullous pemphigoid antigens. However, the 
antigen responsible for the dermal staining has not been identified. 
In this study, we investigated a patient with an atypical bullous 
disease who has autoantibodies that bind to both the dermal and 
epidermal sides of the DE] by IIF on SSS. We demonstrated that the 
patient'S circulating autoantibodies identify two independent and 
distinct basement membrane antigens corresponding to the dermal 
and epidermal staining. 
MATERIALS AND METHODS 
Case Report An 8S-year-old white man with a history of bullous pem-
phigoid (BP) was referred to the dermatology clinic for a recent exacerbation 
of bullous pemphigoid in the gluteal cleft region that was refractory to 
topical steroids. Over the next 3 months, the inflammatory mucocutaneous 
bullous eruption became generalized. Bullous lesions were reminiscent of 
bullous pemphigoid. However, palmo-plantar blisters and extensive muco-
sal involvement (oral, pharyngeal, esophageal, conjunctival, and corneal) 
made the clinical presentation arypical for bullous pemphigoid. No scarring 
or milia was observed at the site of healing lesions. Treatment with a combi. 
nation of azathioprine and prednisone (40 - 80 mg) ameliorated the patient's 
skin condition except for the persistent palmo-plantar and mucosal involve. 
ment. Histopathologic examination oflesional skin revealed a subepidermal 
blister with a mild monolluclear cell infiltrate and occasional eosinophils and 
neutrophils. 
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Direct Immunofluorescence (DIF) Microscopy DIF microscopy was 
performed on the patient's perilesional intact and SSS as previously described 
[14,15). Fluorescein isothiocyanate-conjugated affinity-purified goat anti-
human IgG, IgM, and IgA (Cappel, West Chester, PAl and fluorescein 
isothiocyanate-conjugated rabbit anti-human C3 (Cappel) were used to lo-
cate and define the type of immunoglobulin and complement deposited at 
the DE]. 
Indirect Immunofluorescence (IIF) Microscopy To assess the pres-
ence of circulating IgG anti-basement membrane zone (BMZ) autoanti-
bodies in the patient's serum, IIF microscopy was performed on monkey 
esophagus substrate. To determine the titration of the circulating antibodies 
corresponding to the dermal and epidermal antigens, serial dilutions of the 
patient's serum were used in IIF on normal human SSS [14,15). 
InllDunomapping the l05-kDa Antigen To localize the 10s-kDa an-
tigen in relation to known basement membrane antigens, we performed 
immunofluorescence mapping on SSS and suction-blistered skin substrates 
[14,15] using serum from the previously reported patient with antibodies 
against only the 1 05-kDa antigen [9), a patient with well-characterized BP, a 
mouse monoclonal antibody against type IV collagen, a mouse monoclonal 
antibody against type VII collagen [16), a mouse monoclonal against nicein 
(GB3) [17), and a rabbit polyclonal anti-serum against laminin [14]. To 
assure reproducibility of our immunomapping comparison between salt-
split human skin and suction-blistered human skin, the immunomapping 
was performed on three blisters and three salt-split skin substrates. 
Preparation of Epidermal and Dermal Extracts from 1 M NaCI-
Split Skin Normal human skin specimens were floated in 1 M NaCl, 
1 roM phenylmethylsulfonyl fluoride (PMSF) and 2 mM ethylenediamine 
tetraacetic acid (EDT A) at 4· C for 72 h [5]. Separated epidermis and dermis 
were solubilized with 6 M guanidine hydrochloride, 400 mM Tris-HCI {PH 
8.0),0.1 M p-mercaptoethanol, 50 mM EDTA, and 10 mM cysteine. The 
guanidine-extracted proteins were centrifuged at 10,000 X g for 15 min, 
then the supernatants were dialyzed against cold water for 24 h and lyophi-
lized. The extracts were resuspended in sodium dodecyl sulfate (SDS) sample 
buffer [5,14]. 
Preparation of Epidermal Extract from Suction Blister Suction 
blisters were raised on the normal human skin with a Kiistala suction blister-
ing device [18] as described previously [14]. The blisters were unroofed and 
the proteins solubilized with 2% SDS, 0.125 M Tris-HCl (PH 6.8), 0.1 M 
dithiothreitol (DTT), 0.1 mM EDTA, 1 mM PMSF, and 50 JiM N-ethyl 
maleimide (NEM). The protein extracts were then used for immunoblot 
analysis. 
Preparation of Keratinocyte and Fibroblast Cellular Extracts and 
Culture Media Human neonatal foreskin keratinocytes were initiated 
into culture in a low-calcium, serum-free keratinocyte growth medium 
(KGM; Clone tics, San Diego, CAl. Cultured cells were passaged three times 
to remove any contaminating fibroblasts [19]. At subconfluence, the kerati-
nocytes were trypsinized, extracted in detergent buffer {1 % Nonidet-P-40 
[NP-40], 0.5 M NaCl, 5 mM EDTA, 2 mM DTT, 40 mM Tris (hydroxy-
methyl)-aminomethane [Tris], pH 7.5), and resuspended in SDS sample 
buffer [3] . The keratinocyte culture medium was collected and concentrated 
using a Centricon-sO (Amicon) and resuspended in SDS sample buffer. 
Fibroblast cultures were initiated from newborn foreskins and cultured in 
Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine 
serum. Fibroblasts were trypsinized, harvested, extracted in detergent buffer, 
and resuspended in SDS sample buffer. Fibroblasts were cultured for 24 h in 
serum-free DMEM supplemented with 2% lactalbumin hydrolysate. The 
serum-free culture medium was collected, concentrated, and resuspended as 
above. Protein concentrations of the cellular extracts and culture media were 
determined by Lowry [20] and Bradford assays (Bio-Rad, Hercules, CAl, 
respectively. 
Immunoblot Analyses Experimental serum and control sera were 
reacted by immunoblot analyses [21,22] with extracts of normal human 
cultured keratinocytes and fibroblasts, serum-free conditioned media, epi-
dermal protein extracts of suction blister roofs and SSS, and dermal protein 
extracts from SSS. Our patient's serum was compared with sera from two 
patients with well-characterized epidermolysis bullosa acquisita (EBA)[4], 
five patients with well-characterized BP, one patient with cicatricial pem-
phigoid, five normal humans, and a monoclonal antibody against type VII 
collagen (L3D) (16). Horseradish peroxidase-conjugated goat anti-human 
IgG (heavy chain specific) (Cappel) was used as the secondary antibody, 
followed by standard development with chloronapthol (Bio-Rad). 
To determine the cellular origin of the 10s-kDa protein, equal amounts of 
total protein extracted from human keratinocyte and fibroblast cultures were 
reacted with sera from our patient and the previously reported patient with 
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antibodies against only the 10s-kDa antigen [9]. To determine whether the 
10s-kDa protein was a transmembrane, ex tracellular, or secreted protein, we 
reacted the serum from both patients with equal amounts of protein in 
keratinocyte and fibroblast culture media. 
Immunoblot Analyses with Epitope-Selected Autoantibodies 
Against the lOS-kDa Antigen To demonstrate the absence of cross-
reactivity between the lOs-kDa alltigen and the BP antigens or EBA anti-
gen, and to exclude the possibility that the 10s-kDa antigen was a break-
down product of either of these, patient autoantibodies against the 10s-kDa 
~utoantigen were e~itope selected against the 105-kDa antigen (23) and 
Immunoblotted agamst normal human keratinocyte extracts. Briefly, ex-
tracts of keratinocytes were separated by SDS-polyacrylamide gel electro-
phoresis (PAGE) and electrophoretically transferred to a nitrocellulose filter. 
A horizontal strip of the 105-kDa protein was cut out and incubated over-
night at 4 · C with the patient's serum (1 /s0 dilution). After extensive wash-
ing of the membrane, the bound antibodies were eluted by vigorous agita-
tion in 1 ml of elution buffer (s ruM glycine, 150 mM N aCl, 0.5% Triton 
X 100, pH 2.3) and then neutralized with a 1/10 volume of 50 mM Tris, 
pH 7.4 [23]. 
-
Figure 1. Direct and indirect immunofluorescence of the patient's skin and 
serum. aJ Direct immunofluorescence microscopy of a biopsy taken from the 
patient's skin 1 inch from a lesion and then separated through the DE] by 
incubation in 1 M NaCI. bJ Indirect immunofluorescence using the patient's 
serum diluted 1 : 100 to label normal human skin in which the DE] has been 
fractured by incubation in 1 M NaCI. Both cryostat sections in a and b were 
reacted with fluorescein-conjuga ted goat anti-human IgG. Open arrows, epi-
dermal side and solid arrows, dermal side of the fractured skin. Bar, SO 11m. 
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Figure 2. Immunoblot analysis of the patient's serum 
against dermal and epidermal components. Immunoblot-
ting of our patient's serum (P1), epitope-selected antibod-
ies ofP1 against the 10S-kDa antigen (eP1), bullous pem-
phigoid serum (BP) , a monoclonal antibody against type 
VII collagen (L3D) and normal human sera were reacted 
against proteins extracted from keratinocyte culture (a) or 
dermal proteins isolated from SSS (b), followed by visual-
ization with peroxidase-conj ugated goat anti-human IgG 
(for human sera) or peroxidase-conjugated goat anti-
mouse IgG (for the monoclonal antibody). Arrow, 230 
kDa (a); 290 kDa (b). 
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Direct Immunofluorescence Microscopy DIF performed on 
the patient's intact perilesional skin demonstrated linear deposits of 
IgG at the DE]. When the patient's perilesional SSS was used in the 
same procedure, a linear deposition of IgG on the epidermal and 
dermal side of the DE] was observed (Fig la). Minor amounts ofIgA 
and complement (C3) were deposited along the dermal and epider-
mal side of the fractured skin. No deposits of IgM were detected. 
Indirect Immunofluorescence Microscopy IlF on monkey 
esophagus demonstrated that the patient's serum contained IgG 
autoantibodies that bound to the BMZ. To locate the target of our 
patient's autoantibodies, IIF was performed on normal human SSS. 
The staining pattern revealed that the patient's serum antibodies 
bound both the epidermal and dermal sides of the DE] (Fig 1b). 
Serial dilutions demonstrated an extinction titer of circulating IgG 
twofold higher on the dermal side (1 : 800) than on the epidermal 
cell extract culture medium 
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Figure 3. Comparison of the skin targets by immunoblot ana lysis of the 
autoantibodies of our patient serum (Pt) and the previously described serum 
containing anti - 1 OS-kDa antibodies (P2) (please see reference [9]) . The two 
sera were diluted 1 : 100 and reacted against proteins extracted from cultured 
keratinocyte monolayers or isolated from conditioned culture medium. The 
bound antibodies were visualized by a peroxidase-conjugated goat anti-hu-
man IgG. Arrow, 230 kDa. 
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side (1: 400). No circulating IgA autoantibodies reactive to either 
the dermal side or the epidermal side of SSS were detected in our 
patient, whereas serum from three typical patients with linear IgA 
bullous dermatosis demonstrated IgA antibodies against the epider-
mal side of SSS (not shown). 
Immunoblot Analyses To determine whether the epidermal 
staining seen with immunofluorescence microscopy corresponded 
to the bullous pemphigoid antigens, we reacted our patient'S serum 
and five well-characterized bullous pemphigoid sera against pro-
teins extracted from cultured human keratinocytes. As shown in Fig 
2a, our patient's serum recognized the 230-kDa bullous pemphi-
goid antigen, as did the bullous pemphigoid sera. In addition, our 
B 
A 
Medium Cell Medium Cell 
I I 
Fibroblast Keratinocyte 
Figure 4. The expression of the 105-kDa antigel1 by keratinocyte and 
fibroblast cultures. Irnmlll1oblot ana lysis was performed with Ollr patient'S 
serum against equal amounts of protein extracted from cultured fibroblasts 
and keratinocytes and their correspondin g conditioned media. A) Immuno-
reactivity of the 10S-kDa antigen as detected by Our patient'S serum. B) 
Dosimetry of the corresponding bands. 
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patient's serum clearly recognized another 1 05-kDa epidermal anti-
gen (Fig 2a, falle Pt~ that was not recogl1lzed by any of the bullous 
emphigOid sera (Fig 2a, lalle BP). 
p To determine whether the dermal staining corresponded to the 
EBA antigen (type VII collagen), we compared our patient's serum 
with a monoclonal antibody to type VII collagen by immunoblot 
ana lysis aga.inst proteins extracted from dermis.isolated from SSS. As 
shown in Fig 2b, the monoclonal antibody agallls t type VII collagen 
identified the 290-kDa antigen (falle L3D), previously determined 
to be the alpha chain of type VII collagen (anchoring fibrils), 
whereas our patient's serum did not. Our patient's serum did, how-
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ever, readily label a 105-kDa protein within this dermal extract (Fig 
2b, falle Pt). 
To demonstrate that the 105-kDa antigen was a distinct antigen 
and not a degradation product of the BP or EBA antigen, we per-
formed immunoblot analysis against keratinocyte extracts with our 
patient's epitope-selected autoantibody against the 105-kDa anti-
gen. As shown in Fig 2a (falle ept) the affinity-purified antibody 
identified the 105-kDa antigen, but not the BP or EBA antigen. 
We also compared our patient's serum with that of the previously 
identified patient whose autoantibodies react only against the 105-
kDa antigen [9]. As shown in Fig 3, the 105-kDa band labeled by 
-
Figure 5. Immunomapping of the 1 OS-kDa lamina lucida antigen and a comparison with the other known components of the DE). Indirect immunofluores-
cence was performed using normal human skin in which the DE] was fractured either by incubation in 1 M NaCI (SSS) or by suction blistering. a, c, e) IIF 
performed on SSS; b, d, J) IIF performcd on suction blistcr skin. a, b) IIF sta ining using a bullous pemphigoid patient's serum. c, d) IIF staining using the 
previously described serum [9], which only has antibodies to the 10S-kDa antigen and not to the bullous pemphigoid antigen. e, J) !IF staining using 
anti-nicein antibody (GB3). Epidermis and dermis are labeled E and D, respectively. Solid arrows, side of the staining. Bar, 50 11m. 
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Table 1. Comparative Immunolocalization of the 105-kDa 
Antigen to Other Basement Membrane Components on Salt-
Split and Suction-Blistered Human Skin" 
1 M NaCI-Split Skin (SSS) Suction-Blistered Skin 
(Epidermis/Dermis) (Epidermis/Dermis) 
BP antigen +/- +/-
105 kDa -/+ +/+ 
Laminin -/+ -/+ 
Nicein -/+ -/+ 
Type IV collagen - /+ -/+ 
Type VII collagen -/+ -/+ 
• Location of basement membrane components was assessed by IIF on salt-split and 
suction-blistered human skin using sera from bullous pemphigoid patients, serum from 
the previously reported patient with autoantibodies to only the 105-kD~ antigen ,[91, 
polyclonal antibodies to laminin [14] , the GB,3 monoclonal antibody to rucem/kaltrun 
(a gift from Dt, Patrick Verrando, UruveCSlry of Nice) [17), the DO monoclonal 
antibody to rype VII collagen [16]. and a monoclonal antibody to rype IV collagen [141· 
our patient's serum has electrophoretic migration identical to the 
protein labeled by the serum of the previously identified patient. 
To examine the cellular origin of the 105-kDa antigen and to 
determine whether it is a transmembrane, intracellular, or secreted 
protein, we performed immunoblot analysis against proteins ex-
tracted from cultured mono layers of keratinocytes and fibroblasts 
and compared these with their corresponding conditioned culture 
media. As demonstrated in Fig 4A, our patient's serum recognized a 
105-kDa antigen in protein extracted from both monolayers and 
conditioned medium from both keratinocytes and fibroblasts. Be-
cause equal amounts of total protein were used in these experiments, 
dosimetry of the patient's serum reactivity in these immunoblots 
reflects the relative production of the 105-kDa protein by fibro-
blasts and keratinocytes in vitro. As demonstrated in Fig 4B, the 
similar dosimetric values of the conditioned media and cellular ex-
tracts indicate that both keratinocytes and fibroblasts secrete a simi-
lar amount of the 105-kDa protein. 
Immunolocalization of the 105-kDa Antigen Within the 
BMZ To more precisely delineate the location of the 105-kDa 
protein within the DE], we performed immunomapping ofSSS and 
suction blistered skin with the previously identified patient's serum 
to the 105-kDa antigen [9], sera from two patients with BP, anEBA 
serum, a monoclonal antibody against type VII collagen [16], a 
monoclonal antibody against nice in (GB3) [17), a monoclonal anti-
body against type IV collagen, and antibodies against laminin. As 
demonstrated in Fig 5 and Table I, the BP serum stains only the 
epidermal side of the DE] on both suction-blistered and SSS (Fig 
5a,b), whereas the antibodies against laminin, nicein, type IV colla-
gen, and type VII collagen/EBA antigen stain only the dermal side 
of both substrates (Fig Se,}). In contrast, differential staining was 
observed only with the anti - 1 05-kDa antigen serum. Whereas this 
serum stains only the dermal side of SSS, it stains both the epidermal 
and dermal side of suction-blistered skin (Fig 5c,d) . The labeling was 
identical on three suction blisters tested. These results were con-
firmed by immunoblot analysis of dermal and epidermal extracts 
obtained by suction blister and SSS. The anti-l05-kDa antigen 
serum labeled a 105-kDa protein in both epidermal and dermal 
extracts from suction blisters, but only in the dermal extract from 
SSS (illustration not shown). 
DISCUSSION 
In this study, we analyzed the circulating autoantibodies of a patient 
with an atypical case of bullous pemphigoid whose serum reacts to 
both the dermal and epidermal side of the DE] by IIF on SSS. We 
identified a 105-kDa antigen corresponding to the dermal staining, 
and the 230-kDa bullous pemphigoid antigen corresponding to the 
epidermal staining. Several reports have described patients with 
bullous disorders whose sera recognize separate epitopes on SSS in a 
pattern similar to our patient. In these cases, the epidermal antigens 
were identified as the bullous pemphigoid antigens, whereas the 
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basement membrane antigen responsible for the dermal staining 
was not identified [10,11). In this study, we have identified and 
characterized the l05-kDa dermal antigen as a candidate targeted by 
a subset of "bullous pemphigoid" serum that labels both the dermal 
and epidermal sides of the fractured DE] [10-13]. 
Recently, a patient with a unique subepidermal blistering dis-
order was found to have circulating autoantibodies that bind only 
the dermal side of the DE]. The target of these autoantibodies was 
identified as a new l05-kDa lamina lucida basement membrane 
antigen (9) . This previous report clearly demonstrated that a base-
ment membrane antigen other than type VII collagen can be re-
sponsible for the dermal staining of the DE] by immunofluores-
cence on SSS. Identical electrophoresis migration of the 105-kDa 
antigen identified by our patient and the previously reported patient 
suggest that this antigen is the same in both cases. 
We further localized this novel 105-kDa basement membrane 
autoantigen in relation to other BMZ components by performing 
I1F on suction blister and SSS using anti-105-kDa antigen serum. 
The different staining patterns observed with SSS and suction blister 
skin demonstrate that the cleavage planes of the two substrates are 
separate and distinct. In SSS, the cleavage plane is between the BP 
antigen and the 105-kDa antigen. In suction-blistered skin, how-
ever, the cleavage plane is within the l05-kDa antigen area of the 
lamina lucida, thus lower than that ofSSS. These results, along with 
the identification of the 105-kDa antigen by immunoblot analysis 
on suction-blistered epidermis, demonstrate that the 105-kDa anti-
gen is a unique lamina lucid a antigen that is distinct from other 
basement membrane components and is located between the BP 
antigen and two other lamina lucida proteins, laminin and nicein. 
It is known that keratinocytes and fibroblasts are the two major 
sources of production of the BMZ components. For example, 
human keratinocytes and fibroblasts synthesize fibronectin [241, 
type VII collagen [25,26], and laminin [27]. We have demonstrated 
that keratinocytes and fibroblasts, in vitro, secrete the 105-kDa anti-
gen and produce similar amounts of the 105-kDa protein. As shown 
in this report (Fig 4A), the 105-kDa antigen has the same electro-
phoretic migration whether it is obtained from keratinocyte and 
fibroblast cellular extracts or from the corresponding conditioned 
media (i.e., the secreted form). This suggests that there is no signifi-
cant post-translational modification of the protein. 
Within the basement membrane beneath stratified squamous epi-
thelium there is only one potential candidate macromolecule with a 
molecular weight of lOS kDa that could be the same as the 105-kDa 
protein described in this study. The candidate protein is a compo-
nent of anchoring filaments, which are thin electron-dense struc-
tures below hemidesmosomes that traverse the lamina lucida. An-
choring filament proteins have been described as epiligrin [28]. 
kalinin (29), and BM600/nicein [30). Recent evidence strongly 
suggests that these molecules are identical [30]. This 105-kDa an-
choring filament-associated protein is the product of processing an 
intracellular protein of 155 kDa. This anchoring filament compo-
nent is synthesized only by keratinocytes and not by fibroblasts [28]. 
The 105-kDa basement membrane protein identified by the auto-
antibodies of our patient, and the previously identified patient [9], is 
clearly synthesized by both keratinocytes and fibroblasts, does not 
have an intracellular precursor of higher molecular weight, and 
does not co-localize with BM600/nicein on suction-blistered skin. 
For these reasons, we conclude that the 105-kDa antigen targeted 
by these two patients' autoantibodies is distinct from epiligrin, ka-
linin, and BM600/nicein. 
Another component of the BMZ within the lamina lucida that 
would have a molecular size close to the 105-kDa antigen is the 
antigen described by Zone et al [8]. This 97-kDa antigen is labeled 
specifically by IgA autoantibodies in the sera of patients with linear 
IgA bullous dermatosis. Our patient had no circulating IgA autoan-
tibodies against the BMZ when tested by IIF. Furthermore, the 
97-kDa and the 105-kDa antigen are distinct based on their locali-
zation by immunomapping. The 97 -kDa antigen always localizes to 
the epidermal roof of SSS [8), whereas the l05-kDa antigen always 
localizes to the dermal floor. 
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In conclusion, this study identifies the dermal antigen in a patient 
. th an atypical bullous disease whose serum stains the epidermal :~d dermal side of 1 M NaCI-split skin. This antigen is a novel 
l05-kDa protein located in the lamina lucida above laminin and 
nicein. This lOS-~~a an~ig~n is distinct from the bullous pemphi-
oid antigen, lamuun, mcem, type IV collagen, and type VII coI-F gen. The 10S-kDa antigen is synthesized and secreted by kerat-i~ocytes and fibroblasts with?ut significant post-translati?nal 
modi6cation. ThiS 10S.-kDa antigen ~ay be the sole target antigen 
in some immune-mediated bullous disease or may be a co-target 
associated with bullous pemphigoid antigen. 
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